We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The move comes after US FDA found quality issues like ‘discolouration’ and presence of brown pellets in the company’s 40 mg Esomeprazole Magnesium delayed-release capsules.